Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19
NCT05279391Unknown
- Sponsor
- Democritus University of Thrace
- Start
- Oct 2020
- Primary completion
- Nov 2021
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Replacement Enzymes
- Countries
- 1
01
Overview
Open-label trial of dornase alfa, baricitinib and tocilizumab in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Democritus University of Thrace. Primary endpoint: In-hospital mortality rate at 1 year. Status: unknown.
02
Drugs
dornase alfabaricitinibtocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05279391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279391.